Filing Flows › QHSLab (USAQ) › Q2 2026 › vs Q2 2025
QHSLab (USAQ) Q2 2026 vs Q2 2025 (year over year)
QHSLab's revenue rose $242K (+40%) from $605K in Q2 2025 to $847K in Q2 2026. The biggest changes: Integrated Service Program +$228K (+86%); Immunotherapy Treatment Sales −$26K (-22%); Training and Other Revenue +$14K (+280%). Gross margin 69.6% against 65.9% (+3.7 pts).
QHSLab, Q2 2026: revenue $847K (+40% year over year), operating margin 5.3%, net earnings $38K, operating cash flow −$8K. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 69.6% | 65.9% | +3.7 pts |
| Operating margin | 5.3% | 1.9% | +3.4 pts |
| Net margin | 4.5% | -8.7% | +13.2 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Integrated Service Program | $491K | $264K | $228K | +86% |
| Allergy Diagnostic Kit Sales | $196K | $198K | −$2K | -0.8% |
| Immunotherapy Treatment Sales | $94K | $120K | −$26K | -22% |
| Training and Other Revenue | $19K | $5K | $14K | +280% |
| Shipping and Handling | $11K | $10K | $1K | +8% |
| Subscription Revenue | $7K | $9K | −$3K | -28% |
| Revenue | $847K | $605K | $242K | +40% |
| Gross profit | $590K | $399K | $191K | +48% |
| Cost of revenue | $258K | $206K | $51K | +25% |
| Operating profit | $45K | $12K | $34K | +293% |
| Operating expenses | $545K | $387K | $157K | +41% |
| Pre-tax earnings | $38K | −$53K | $91K | — |
| Other expense, net | $7K | $64K | −$57K | -89% |
| Research & development | $115K | $112K | $2K | +2% |
| Sales & marketing | $156K | $107K | $49K | +46% |
| General & admin | $255K | $150K | $106K | +70% |
| Other operating costs | $18K | $18K | $0 | 0% |
| Net earnings | $38K | −$53K | $91K | — |
| Operating cash sources | $64K | −$162K | $226K | — |
| Depreciation & amortization | $18K | $18K | $0 | 0% |
| Cash used in operations | $8K | −$127K | $135K | — |
| Working capital & other | $64K | −$162K | $226K | — |
Questions
How much did QHSLab's revenue grow year over year in Q2 2026?
QHSLab's revenue rose $242K (+40%) from $605K in Q2 2025 to $847K in Q2 2026.
What drove QHSLab's revenue change in Q2 2026?
Integrated Service Program +$228K (+86%); Immunotherapy Treatment Sales −$26K (-22%); Training and Other Revenue +$14K (+280%).